Lou Reese - Mar 7, 2023 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role
Executive Chairman., Director
Signature
/s/ Rene Paula Molina as Attorney-in-Fact for Lou Reese
Stock symbol
VAXX
Transactions as of
Mar 7, 2023
Transactions value $
$0
Form type
4
Date filed
4/5/2023, 04:48 PM
Previous filing
Jun 21, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Stock Option (right to buy) Award $0 +620K $0.00 620K Mar 7, 2023 Class A Common Stock 620K $2.29 Direct F1
transaction VAXX Stock Option (right to buy) Award $0 +61.6K $0.00 61.6K Mar 7, 2023 Class A Common Stock 61.6K $2.29 Direct F2
transaction VAXX Stock Option (right to buy) Award $0 +301K $0.00 301K Mar 7, 2023 Class A Common Stock 301K $2.29 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 48 equal monthly installments beginning on March 7, 2023.
F2 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options are fully vested upon issuance. This one-time option grant was made in lieu of an annual cash bonus payment to Mr. Reese.
F3 The options were issued to the Reporting Person pursuant to the Issuer's 2021 Omnibus Incentive Compensation Plan. Such options vest in 12 equal monthly installments beginning on January 1, 2023. The one-time option grant was made in consideration of Mr. Reese waiving his salary for fiscal years 2022 and 2023.

Remarks:

Executive Chairman.